Europe must rethink medicine pricing or risk losing investments, pharma lobby chief says

Europe's pharmaceutical industry says governments need to rethink drug pricing or risk losing manufacturing investment and clinical trials. The warning points to growing pressure on pharma economics across the region, with potential implications for investment allocation and supply-chain decisions. The piece is cautionary rather than event-driven, but it highlights a sector-level policy risk that could weigh on European healthcare assets.

Analysis

Europe's pharmaceutical industry says governments need to rethink drug pricing or risk losing manufacturing investment and clinical trials. The warning points to growing pressure on pharma economics across the region, with potential implications for investment allocation and supply-chain decisions. The piece is cautionary rather than event-driven, but it highlights a sector-level policy risk that could weigh on European healthcare assets.